PIPELINE EMBOLIZATION DEVICE
Micro Therapeutics, Inc. d/b/a ev3 Neurovascular · Decision date Feb 20, 2026
What did the FDA approve?
FDA records P100018/S052 as a supplement to PMA P100018, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Feb 20, 2026.
FDA approval order statement
Approval of claims regarding reduced material thrombogenicity of a proprietary surface modification for the Pipeline Flex Embolization Device with Shield Technology and Pipeline Vantage Embolization Device with Shield Technology supported by acute benchtop in-vitro testing.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Feb 20, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P100018/S052
- Regulatory pathway
- PMA supplement
- Product code
- OUT
- Decision code
- APPR
- Decision date
- Feb 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intracranial aneurysm flow diverter.
- Product code
- OUT
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P100018/S048 · Related supplement
Pipeline Vantage Embolization Device with Shield Technology
P100018/S052 received
Application receipt date recorded by FDA.
P100018/S052 · FDA decision
Real-Time Process
P100018/S053 · Related supplement
Pipeline Flex Embolization Device (Pipeline Flex); Pipeline Flex Embolization Device with Shield Technology (Pipelin
P100018/S054 · Related supplement
Pipeline Flex Embolization Device with Shield Technology (Pipeline Shield); Pipeline Vantage Embolization Device wit
P100018/S055 · Related supplement
Pipeline Flex Embolization Device (Pipeline Flex); Pipeline Flex Embolization Device with Shield Technology (Pipelin
Timeline entries are records held by MedtechLedger for P100018. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100018
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | Aug 14, 2025 | FDA | |
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | May 15, 2026 | FDA | |
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | Jun 26, 2026 | FDA | |
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | Jul 21, 2026 | FDA |
Explore the linked device profile
Other records with product code OUT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Surpass Elite Flow DiverterP170024/S027 | Stryker Neurovascular | PMA supplement | Aug 28, 2026 | FDA |
Surpass Evolve; Surpass Elite FDSP170024/S026 | Stryker Neurovascular | PMA supplement | Jun 26, 2026 | FDA |
| Microvention, Inc. | PMA supplement | Nov 2, 2025 | FDA | |
| Microvention, Inc. | PMA supplement | Sep 20, 2025 | FDA | |
FRED X SystemP180027/S014 | Microvention, Inc. | PMA supplement | Sep 18, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Micro Therapeutics, Inc. d/b/a ev3 Neurovascular
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 9775 Toledo Way, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P100018/S052
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





